| Popis: |
Bromodomain-containing protein 4 (BRD4) is one of the most important members in the bromodomain and extra terminal domain(BET) family, it plays an important role in cellular physiology in human body, such as cell cycles, cell proliferation, and immune response. Recent studies have shown that BRD4 is associated with occurrence and development of acute myeloblastic leukemia, multiple myeloma and lymphoma. The mechanisms of BRD4 in hematologic malignancies including the regulation of c-Myc expression, and participation of the composition of super-enhancer, etc. At present, many kinds of inhibitors have been developed to target inhibit BRD4 for therapy in hematologic malignancies, and some of BRD4 inhibitors have entered phase Ⅱ clinical trials, which suggested that BRD4 inhibitors are expected to become new therapeutic agents for hematologic malignancies. In this review, the research advance of BRD4 and BRD4 inhibitors in hematologic malignancies was summarized briefly.BRD4及其抑制剂在血液肿瘤中的研究进展.溴结构域蛋白4（BRD4）是溴结构域与超末端结构域（BET）家族中最重要的功能蛋白，它参与了人体内细胞周期、细胞增殖、免疫反应等生理功能。有多个研究显示，BRD4与急性髓细胞白血病、多发性骨髓瘤及淋巴瘤等多种血液肿瘤的发生发展密切相关，BRD4在血液肿瘤中的作用机制包括调控c-Myc的转录、参与超级增强子的组成等。目前，已研制出多种靶向BRD4的抑制剂，部分BRD4抑制剂已进入血液肿瘤治疗的Ⅱ期临床试验，有望成为血液肿瘤的新靶向治疗药物。本文主要就BRD4及BRD4抑制剂在血液肿瘤中的最新研究进展作一综述. |
